Because there are differing opinions regarding treatment of patients in the chronic phase of
chronic myeloid leukemia (CML), the American Society of Hematology convened an expert …

Achieving a complete cytogenetic response (CCgR) is a major target in the treatment of
chronic myeloid leukemia (CML) with interferon-α (IFN-α), but CCgRs are rare. The mean …

PURPOSE: To determine the response rate to interferon-alpha (IFN-α) in patients with
chronic myelogenous leukemia (CML) aged 60 years and older. PATIENTS AND …

Chronic myelogenous leukemia (CML) is a chronic myeloproliferative disorder with an
initially chronic course lasting for 3–5 years. It eventually transforms into accelerated and …

Chronic myeloid leukemia (CML) in older patients has not been studied well. To assess the
long-term outcome of older patients with Philadelphia-and/or BCR-ABL-positive CML, 199 …

PURPOSE Since interferon alfa (IFN-A) became an established treatment in chronic
myelogenous leukemia (CML), more patients are referred to tertiary centers in late chronic …

We studied the clinical course of 130 chronic myeloid leukemia (CML) patients (89 males
and 41 females) in the European Bone Marrow Transplantation Group (EBMT) registry who …

The choice of primary treatment for patients with chronic myeloid leukemia (CML) diagnosed
in chronic phase has become exceedingly difficult. There is little doubt that allogeneic stem …

PURPOSE To determine whether prior interferon alfa (IFN-A) treatment affects the outcome
of allogeneic bone marrow transplantation. PATIENTS AND METHODS We analyzed the …

BACKGROUND Homoharringtonine (HHT) has antileukemic activity in patients with
Philadelphia chromosome (Ph) positive chronic myelogenous leukemia (CML) …